Home > Cardiology > ACC 2022 > Prevention > Lipoprotein(a) slashed by 98% in APOLLO trial

Lipoprotein(a) slashed by 98% in APOLLO trial

Presented By
Prof. Steven Nissen, Cleveland Clinic, USA
Conference
ACC 2022
Trial
Phase 1, APOLLO
Doi
https://doi.org/10.55788/efc5d5ef
Results from the first-in-human, phase 1 APOLLO study showed that the investigational short interfering RNA (siRNA) therapy called SLN360 was safe and lowered lipoprotein(a) (Lp[a]) by up to 98%. Prof. Steven Nissen (Cleveland Clinic, OH, USA) presented the findings of the phase 1 APOLLO study (NCT04606602), which was simultaneously published in JAMA [1,2]. The primary outcome measures of APOLLO were the safety, tolerability, pharmacokinetics, and pharmacodynamics of SLN360 after single ascending subcutaneous doses in 32 participants with elevated Lp(a) levels and no known cardiovascular disease. The main secondary outcome was a change in Lp(a) plasma concentration after a follow-up of no more than 150 days. Prof. Nissen explained that study participants (mean age 50 years; 53% women) were randomised into several cohorts to receive either placebo (n...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on